Mader RM - Search Results

1

Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.

Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlböck M, Jakesz R. Taucher S, et al. Among authors: mader rm. Breast Cancer Res Treat. 2003 Dec;82(3):207-13. doi: 10.1023/B:BREA.0000004378.15859.51. Breast Cancer Res Treat. 2003. PMID: 14703068

2

Cutaneous reactions to GM-CSF in inflammatory breast cancer.

Steger GG, Locker G, Rainer H, Mader RM, Sieder AE, Gnant MF, Aberer W, Jakesz R. Steger GG, et al. Among authors: mader rm. N Engl J Med. 1992 Jul 23;327(4):286. doi: 10.1056/NEJM199207233270420. N Engl J Med. 1992. PMID: 1535420 Clinical Trial. No abstract available.

3

Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses.

Steger GG, Wrba F, Mader R, Schlappack O, Dittrich C, Rainer H. Steger GG, et al. Eur J Cancer. 1991;27(3):254-6. doi: 10.1016/0277-5379(91)90509-c. Eur J Cancer. 1991. PMID: 1827307

4

Instability of the anticancer agent etoposide under in vitro culture conditions.

Mader RM, Steger GG, Moser K, Rainer H, Krenmayr P, Dittrich C. Mader RM, et al. Cancer Chemother Pharmacol. 1991;27(5):354-60. doi: 10.1007/BF00688857. Cancer Chemother Pharmacol. 1991. PMID: 1998995

5

Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.

Steger GG, Mader R, Derfler K, Moser K, Dittrich C. Steger GG, et al. Klin Wochenschr. 1989 Aug 17;67(16):813-7. doi: 10.1007/BF01725197. Klin Wochenschr. 1989. PMID: 2796251

6

Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.

Steger GG, Dittrich C, Schlappack O, Mader R, Herold C, Brade WP, Keller A, Moser K. Steger GG, et al. J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184. J Cancer Res Clin Oncol. 1988. PMID: 3144554

7

Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.

Mader RM, Zilg H, Schlappack O, Steger GG, Baur M, Greifenberg B, Heberle U, Dittrich C. Mader RM, et al. Cancer Chemother Pharmacol. 1995;37(1-2):91-6. doi: 10.1007/BF00685634. Cancer Chemother Pharmacol. 1995. PMID: 7497603 Clinical Trial.

8

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?

Locker GJ, Simonitsch I, Mader RM, Warlamides E, Gnant MF, Jakesz R, Rainer H, Steger GG. Locker GJ, et al. Among authors: mader rm. Breast Cancer Res Treat. 1995 Jun;34(3):213-9. doi: 10.1007/BF00689712. Breast Cancer Res Treat. 1995. PMID: 7579485 Clinical Trial.

9

Different stereospecific protein binding of tetrahydrofolates to human serum albumin.

Mader RM, Steger GG, Rizovski B, Jakesz R, Rainer H. Mader RM, et al. J Pharm Sci. 1994 Sep;83(9):1247-9. doi: 10.1002/jps.2600830912. J Pharm Sci. 1994. PMID: 7830239

10

New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.

Locker GJ, Mader RM, Braun J, Sieder AE, Marosi C, Rainer H, Jakesz R, Steger GG. Locker GJ, et al. Among authors: mader rm. Oncology. 1995 Mar-Apr;52(2):140-4. doi: 10.1159/000227445. Oncology. 1995. PMID: 7854774

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters